Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance, first issued 18 August 2022

This interim recommendation pertains to the COVID-19 Valneva vaccine (VLA2001), developed by Valneva’s research and development teams in France and Austria with the marketing authorization holder, Valneva Austria GmbH. In the subsequent text the vaccine will be referred to as VLA2001.